For healthcare investors, though, it represented yet another reason to dump some stock. Trump’s appointment of industry ...
By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback